A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation

Genetic Vaccines and Therapy

Volumn 8, Issue , 2010, Pages

  Alyamkina, Ekaterina A ^a,b   Nikolin, Valeriy P ^b   Popova, Nelly A ^a,b   Dolgova, Evgenia V ^a,b   Proskurina, Anastasia S ^b   Orishchenko, Konstantin E ^b   Efremov, Yaroslav R ^b   Chernykh, Elena R ^c   Ostanin, Alexandr A ^c   Sidorov, Sergey V ^d   Ponomarenko, Dmitriy M ^e   Zagrebelniy, Stanislav N ^a   Bogachev, Sergey S ^b   Shurdov, Mikhail A ^f  

^a NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^d Municipal Hospital   (Russian Federation)

^e Regional Oncologic Dispensary   (Russian Federation)

^f LLC Panagen ^*  (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD34 ANTIBODY; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; DOUBLE STRANDED DNA; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOMA; CELL ACTIVATION; CELL ISOLATION; CELL MATURATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DNA ISOLATION; HUMAN; LEUKOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; SPLEEN; STUDENT T TEST; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

MUS;

EID: 77958544014     PISSN: None     EISSN: 14790556     Source Type: Journal    
DOI: 10.1186/1479-0556-8-7     Document Type: Article

References (60)

1. Granov AM, Molchanov OE. Carcinogenesis and tumor immunobiology. Basic and clinical aspects. Vopr Onkol 2008, 54:401-409. In Russian.
2. Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J Immunol 2005, 174:2457-2465.
3. Olishevsky SV, Kozak VV, Yanish Y, Rybalko SL, Shliakhovenko VA. Immunostimulatory CpG DNA: prospects for clinical use in oncology. Oncologia 2006, 8:209-217. In Russian.
4. Baldueva IA. Antitumor vaccines. Applied oncology 2003, 4:157-166. In Russian.
5. Ishii KJ, Kawakami K, Gursel I, Conover J, Joshi BH, Klinman DM, Puri RK. Antitumor therapy with bacterial DNA and toxin: complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin Cancer Res 2003, 9:6516-6522.
6. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003, 9:3105-3114.
7. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004, 4:249-258. 10.1038/nri1329, 15057783.
8. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006, 5:471-484. 10.1038/nrd2059, 16763660.
9. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007, 117:1184-1194. 10.1172/JCI31414, 1857270, 17476348.
10. Lee MS, Kim YJ. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 2007, 76:447-480. 10.1146/annurev.biochem.76.060605.122847, 17328678.
11. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826. 10.1038/nature06246, 17943118.
12. Rakoff-Naum S, Medzhitov R. Role of Toll-like receptors in tissue repair and carcinogenesis. Biokhimia 2008, 73:690-698. In Russian.
13. Berejnoy AE, Gnuchev NV, Georgiev GP, Kozlov AM, Larin SS. Molecular mechanisms of interaction between tumor and the immune system. Vopr Onkol 2008, 54:669-683. In Russian.
14. Alyamkina EA, Dolgova EV, Likhacheva AS, Rogachev VA, Sebeleva TE, Nikolin VP, Popova NA, Kiseleva EV, Orishchenko KE, Sakhno LV, Gel'fgat EL, Ostanin AA, Chernykh ER, Zagrebelniy SN, Bogachev SS, Shurdov MA. Exogenous allogenic fragmented double-stranded DNA is internalized into human dendritic cells and enhances their allostimulatory activity. Cell Immunol 2010, 262:120-126. 10.1016/j.cellimm.2010.01.005, 20170907.
15. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM. Genomic DNA released by dying cells induces the maturation of APCs. J Immunol 2001, 167:2602-2607.
16. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996, 184:465-472. 10.1084/jem.184.2.465, 2192710, 8760800.
17. Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, MacDonald HR. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003, 111:1673-1681. 156105, 12782670.
18. Zhang S, Li WF, Zhang HJ, Wang Q. Antitumor reactivity of splenocytes primed in vivo with dendritic-cell-based vaccine and secondarily activated with a cocktail of cytokines in vitro. Exp Oncol 2004, 26:243-245.
19. Dullaers M, Van Meirvenne S, Heirman C, Straetman L, Bonehill A, Aerts JL, Thielemans K, Breckpot K. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther 2006, 13:630-640. 10.1038/sj.gt.3302697, 16355115.
20. Kim JH, Majumder N, Lin H, Watkins S, Falo LD, You Z. Induction of therapeutic antitumor immunity by in vivo administration of a lentiviral vaccine. Hum Gene Ther 2005, 16:1255-1266. 10.1089/hum.2005.16.1255, 16259559.
21. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G, Lemonnier F, Zitvogel L. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006, 176:2722-2729.
22. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin 2008, 4:453-456.
23. Martin DA, Elkon KB. Intracellular mammalian DNA stimulates myeloid dendritic cells to produce type I interferons predominantly through a toll-like receptor 9-independent pathway. Arthritis Rheum 2006, 54:951-962. 10.1002/art.21677, 16508978.
24. Ishii KJ, Akira S. Innate immune recognition of, and regulation by, DNA. Trends Immunol 2006, 27:525-532. 10.1016/j.it.2006.09.002, 16979939.
25. Shirota H, Ishii KJ, Takakuwa H, Klinman DM. Contribution of interferon-beta to the immune activation induced by double-stranded DNA. Immunology 2006, 118:302-310. 10.1111/j.1365-2567.2006.02367.x, 1782301, 16827891.
26. Ishii KJ, Kawagoe T, Koyama S, Matsui K, Kumar H, Kawai T, Uematsu S, Takeuchi O, Takeshita F, Coban C, Akira S. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008, 451:725-729. 10.1038/nature06537, 18256672.
27. Takeshita F, Ishii KJ. Intracellular DNA sensors in immunity. Curr Opin Immunol 2008, 20:383-388. 10.1016/j.coi.2008.05.009, 18573338.
28. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949. 10.1038/nm1093, 15322536.
29. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999, 59:3128-3133.
30. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity by removing. J Immunol 1999, 163:5211-5218.
31. Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, Borras-Cuesta F, Lasarte JJ. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol 2003, 171:5931-5939.
32. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005, 105:2862-2868. 10.1182/blood-2004-06-2410, 15591121.
33. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005, 201:1591-1602. 10.1084/jem.20042167, 2212915, 15883172.
34. Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci 2005, 39:105-112. 10.1016/j.jdermsci.2005.02.002, 15899580.
35. Motoyoshi Y, Kaminoda K, Saitoh O, Hamasaki K, Nakao K, Ishii N, Nagayama Y, Eguchi K. Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 2006, 16:141-146.
36. Darrasse-Jeze G, Deroubaix S, Mouquet H, Victora GD, Eisenreich T, Yao KH, Masilamani RF, Dustin ML, Rudensky A, Liu K, Nussenzweig MC. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med 2009, 206:1853-1862. 10.1084/jem.20090746, 2737156, 19667061.
37. Nakahara T, Uchi H, Lesokhin AM, Avogadri F, Rizzuto GA, Hirschhorn-Cymerman D, Panageas KS, Merghoub T, Wolchok JD, Houghton AN. Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood 2010, 115:4384-4392. 10.1182/blood-2009-11-251231, 20154220.
38. Salem ML, El-Naggar SA, Cole DJ. Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo. Cell Immunol 2010, 261:134-143. 10.1016/j.cellimm.2009.11.011, 20036354.
39. Alyamkina EA, Dolgova EV, Likhacheva AS, Rogachev VA, Sebeleva TE, Nikolin VP, Popova NA, Orishchenko KE, Strunkin DN, Chernykh ER, Zagrebelniy SN, Bogachev SS, Shurdov MA. Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. Genet Vaccines Ther 2009, 7:12. 10.1186/1479-0556-7-12, 2732619, 19682353.
40. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123:321-334. 10.1016/j.cell.2005.08.032, 16239148.
41. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res 2007, 67:7941-7944. 10.1158/0008-5472.CAN-07-1622, 17804698.
42. Henson PM, Hume DA. Apoptotic cell removal in development and tissue homeostasis. Trends Immunol 2006, 27:244-250. 10.1016/j.it.2006.03.005, 16584921.
43. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001, 61:3689-3697.
44. Yushok WD, Mallalieu LJ, Batt WG. Properties of Krebs 2 ascites carcinoma cells: Weight, size, specific gravity, and protein content. Journal of the Franklin Institute 1956, 262:507-509.
45. Poteryaeva ON, Falameeva OV, Zhanaeva SY, Svechnikova IG, Korolenko TA, Kaledin VI. Role of cystatin C and cysteine proteinases in the development of mouse LS-lymphosarcoma. Bull Exp Biol Med 2001, 132:675-677. 10.1023/A:1012584429734, 11687851.
46. Nikolin VP, Kaledin VI, Baimak T, Galiamova MR, Popova NA, Voitsitskii VE. Apoptosis-inducing and anti-tumor effect of cyclophosphamide, cisplatin and adriamycin used separately or combined in murine lymphosarcoma LS. Vopr Onkol 2002, 48:211-215. In Russian.
47. Alyamkina EA, Leplina OY, Sakhno LV, Chernykh ER, Ostanin AA, Efremov YR, Shilov AG, Proskurina AS, Orishchenko KE, Dolgova EV, Rogachev VA, Nikolin VP, Popova NA, Zagrebelniy SN, Bogachev SS, Shurdov MA. Effect of double-stranded DNA on maturation of dendritic cells in vitro. Cell Immunol 2010, PMID: 20863487.
48. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 1996, 93:12445-12450. 10.1073/pnas.93.22.12445, 38011, 8901601.
49. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, Hayday AC. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001, 294:605-609. 10.1126/science.1063916, 11567106.
50. Nikolin VP, Popova NA, Sebeleva TE, Strunkin DN, Rogachev VA, Semenov DV, Bogachev SS, Yakubov LA, Shurdov MA. Effect of exogenous DNA injection on leukopoietic repair and antitumor action of cyclophosphamide. Vopr Onkol 2006, 52:336-340. In Russian.
51. Chabner B, Longo DL. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, Lippincott Willians & Wilkins 2006,
52. Mayer RJ. Targeted therapy for advanced colorectal cancer--more is not always better. N Engl J Med 2009, 360:623-625. 10.1056/NEJMe0809343, 19196680.
53. Obeid M. ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin. J Immunol 2008, 181:2533-2543.
54. Khochenkov DM. Biology of dendritic cells. Biological membranes 2008, 25:403-419. In Russian.
55. Lutsiak ME, Tagaya Y, Adams AJ, Schlom J, Sabzevari H. Tumor-induced impairment of TCR signaling results in compromised functionality of tumor-infiltrating regulatory T cells. J Immunol 2008, 180:5871-5881. 2636572, 18424706.
56. Correale P, Cusi MG, Tsang KY, Del Vecchio MT, Marsili S, Placa ML, Intrivici C, Aquino A, Micheli L, Nencini C, Ferrari F, Giorgi G, Bonmassar E, Francini G. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 2005, 23:8950-8958. 10.1200/JCO.2005.12.147, 16061910.
57. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C, Menard S, Balsari A. Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005, 65:6388-6393. 10.1158/0008-5472.CAN-05-0602, 16024642.
58. Bopp T, Radsak M, Schmitt E, Schild H. New strategies for the manipulation of adaptive immune responses. Cancer Immunol Immunother 2010, 59:1443-1448. 10.1007/s00262-010-0851-z, 20361184.
59. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004, 34:336-344. 10.1002/eji.200324181, 14768038.
60. Nikolin VP, Popova NA, Sebeleva TE, Strunkin DN, Rogachev VA, Semenov DV, Bogachev SS, Yakubov LA, Shurdov MA. Effect of exogenous DNA on the growth of transplantable tumors. Vopr Onkol 2006, 52:66-69. In Russian.